The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

The complications portend a rise in the arrhythmia, and also in mortality, with an average time to event of 7 years.

The instructions for use have been updated to address issues that led to a greater risk of neurovascular events in an early ...

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Using the BiovitalsHF software to personalize recommendations got more patients on all four pillars of therapy.

Much of the conversation at THT revolved around how use of the device would be handled outside of specialized centers.

These early data are reassuring, but there are many questions yet to be explored in the upcoming pivotal trial, Nancy ...

Not everyone agrees: one expert says it would be more helpful to consider imaging as a quality measure at the local level.

While researchers are grateful they can offer patients one of the two approved stabilizers, better therapeutics are still ...

The main results of the SUMMIT trial, reported last year, showed that tirzepatide—a dual glucose-dependent insulinotropic ...

The findings are disappointing, but questions around intervention timing, patient population, and others remain to be ...

The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.